A. Chi

P. Brastianos, H. Shih, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA

B. Rosen, Jayashree Kalpathy-Cramer, P. Wen, 2014 .

Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201

S. Khatua, M. Mehta, P. Wen, 2019, Journal of Neuro-Oncology.

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.

M. Mehta, T. Niazi, W. Oster, 2019, Journal of neurosurgery. Pediatrics.

Targeting Hypoxia-Inducible Factor 1&agr; in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment

D. Louis, Anoop P. Patel, H. Wakimoto, 2015, Journal of neuropathology and experimental neurology.

ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA

M. Mehta, P. Wen, T. Cloughesy, 2019, Neuro-Oncology.

Quantitative sodium imaging and gliomas: a feasibility study

D. Kondziolka, J. Golfinos, R. Jain, 2018, Neuroradiology.

Musculoskeletal Outside Interpretation (MOI-RADS): an automated quality assurance tool to prospectively track discrepancies in second-opinion interpretations in musculoskeletal imaging

T. Cook, M. A. Bedoya, A. Chi, 2020, Skeletal Radiology.

Is there a role for bevacizumab in the treatment of glioblastoma?

M. Chamberlain, A. Chi, 2013, The oncologist.

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

B. Rosen, A. Iafrate, Jayashree Kalpathy-Cramer, 2013, Proceedings of the National Academy of Sciences.

Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

B. Rosen, A. Sorensen, D. Cahill, 2013, The Journal of clinical investigation.

Phase Ib study of cediranib in combination with daily temozolomide and radiation in patients with newly diagnosed glioblastoma.

P. Wen, A. Sorensen, T. Batchelor, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acknowledgement of Reviewers 2012

Steven D Chang, A. Friedman, D. Brat, 2013, Dysphagia (New York. Print).

Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2013 .

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma

H. Wakimoto, D. Cahill, J. Golfinos, 2018, Clinical Cancer Research.

Blockade of transforming growth factor‐β signaling enhances oncolytic herpes simplex virus efficacy in patient‐derived recurrent glioblastoma models

A. Iafrate, H. Wakimoto, D. Cahill, 2017, International journal of cancer.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

A. Iafrate, D. Louis, H. Wakimoto, 2014, Cancer discovery.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Simon Kasif, Esther Rheinbay, Mohammad Shahid, 2013, Cell reports.

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Maristela L Onozato, A. Iafrate, K. Flaherty, 2016, Clinical Cancer Research.

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

Maristela L Onozato, A. Iafrate, H. Wakimoto, 2019, Scientific Reports.

GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth

A. Heguy, J. Golfinos, M. Snuderl, 2016, Oncogenesis.

Inhibiting kinases in malignant gliomas

P. Wen, A. Chi, 2007, Expert opinion on therapeutic targets.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

A. Iafrate, P. Wen, D. Cahill, 2018, Nature Communications.

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

A. Iafrate, H. Wakimoto, D. Cahill, 2014, Clinical Cancer Research.

Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy

Aristotelis Tsirigos, Yansong Peng, Jie Tong, 2020, eLife.

Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Jennie W. Taylor, R. Jain, A. Stemmer-Rachamimov, 2013, Neuro-oncology.

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

A. Iafrate, D. Louis, D. Cahill, 2019, Acta neuropathologica communications.

Rbm15 Modulates Notch-Induced Transcriptional Activation and Affects Myeloid Differentiation

C. Niu, S. Morris, A. Chi, 2007, Molecular and Cellular Biology.

Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas

J. Golfinos, R. Jain, M. Snuderl, 2018, American Journal of Neuroradiology.

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

A. Iafrate, H. Wakimoto, D. Cahill, 2019, Clinical Cancer Research.

GC-Rich Sequence Elements Recruit PRC2 in Mammalian ES Cells

Bradley E. Bernstein, Biju Issac, B. Bernstein, 2010, PLoS genetics.

Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains

Simon Kasif, Eric S. Lander, Bradley E. Bernstein, 2008, PLoS genetics.

Inhibiting angiogenesis in malignant gliomas.

P. Wen, A. Chi, 2012, Handbook of clinical neurology.

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.

T. Mikkelsen, A. Iafrate, P. Wen, 2020, JCO precision oncology.

Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

A. Iafrate, J. Reis-Filho, B. Weigelt, 2019, Scientific Reports.

Extreme Vulnerability of ID H 1 Mutant Cancers to NAD + Depletion Graphical Abstract Highlights

A. Iafrate, K. Flaherty, H. Wakimoto, 2022 .

Expression profiling of the adhesion G protein-coupled receptor GPR133 (ADGRD1) in glioma subtypes

James X. Sun, T. Schöneberg, R. Jain, 2020, Neuro-oncology advances.

TargetableSignalingPathwayMutationsAreAssociatedwith Malignant Phenotype in IDH-Mutant Gliomas

A. Iafrate, H. Wakimoto, D. Cahill, 2014 .

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.

Jennie W. Taylor, D. Cahill, A. Chi, 2013, Oncology.

Neuro-Oncology Practice Clinical Debate: Early treatment or observation for patients with newly diagnosed oligodendroglioma and small-volume residual disease.

J. Nakamura, A. Chi, L. Boreta, 2020, Neuro-oncology practice.

Chapter 9 – Chemotherapeutics and Their Efficacy

A. Chi, H. W. Phillips, H. Phillips, 2016 .

PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma

A. Iafrate, D. Louis, D. Cahill, 2019, Acta Neuropathologica Communications.

Angiogenesis as a therapeutic target in malignant gliomas.

Tracy T Batchelor, A Gregory Sorensen, Rakesh K Jain, 2009, The oncologist.

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

P. Brastianos, A. Shaw, A. Chi, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma

Jennie W. Taylor, P. Wen, D. Cahill, 2014, Journal of Neuro-Oncology.

Inhibition of angiogenesis and invasion in malignant gliomas

P. Wen, A. Norden, A. Chi, 2007, Expert review of anticancer therapy.

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

P. Wen, T. Batchelor, W. Oster, 2017, Oncotarget.

Radiogenomics identifying important biological pathways in gliomas.

R. Jain, A. Chi, 2021, Neuro-oncology.

BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults.

A. Iafrate, D. Louis, D. Dias-Santagata, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Xiaohong Yan, P. Jänne, A. Tolcher, 2021 .

A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Y. Fujii, H. Wakimoto, D. Cahill, 2020, Cancer Research.

Genotype-targeted local therapy of glioma

Ameya R. Kirtane, Julie M. Batten, M. Meyerson, 2018, Proceedings of the National Academy of Sciences.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

A. Iafrate, D. Cahill, B. Nahed, 2016, The oncologist.

Antiangiogenic strategies for treatment of malignant gliomas

P. Wen, A. Norden, A. Chi, 2009, Neurotherapeutics.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Katrina H. Smith, R. Beroukhim, P. Wen, 2015, Neuro-oncology.

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor.

Jeffrey W. Clark, A. Iafrate, D. Louis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case records of the Massachusetts General Hospital. Case 8-2014. A 29-year-old man with headache, vomiting, and diplopia.

D. Louis, P. Schaefer, A. Chi, 2014, The New England journal of medicine.

Prospective, high-throughput molecular profiling of human gliomas

A. Iafrate, P. Wen, K. Ligon, 2012, Journal of Neuro-Oncology.

Update on Glioma Treatments in the United States

A. Iafrate, P. Wen, D. Louis, 2013 .

Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma.

A. Iafrate, D. Louis, T. Batchelor, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study

Rameen Beroukhim, Rebecca A. Betensky, Tracy T. Batchelor, 2014, Journal of Neuro-Oncology.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Sankha S. Basu, Susan M. Chang, W. Yung, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case 8-2014: A man with headache, vomiting, and diplopia.

Tracey A. Cho, P. Schaefer, A. Chi, 2014, The New England journal of medicine.

Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma.

D. Louis, D. Cahill, A. Chi, 2016, The New England journal of medicine.

Assessing the Need for Preprocedural Laboratory Tests and Stopping Non-steroidal Anti-inflammatory Drugs/Aspirin in Patients Undergoing Percutaneous Bone and Soft Tissue Biopsies

L. Fleisher, R. Sebro, S. Trerotola, 2019, CardioVascular and Interventional Radiology.

Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

T. Wurdinger, H. Wakimoto, P. Wesseling, 2018, Neuro-oncology.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Neel S. Madhukar, O. Elemento, U. McDermott, 2017, PloS one.

Identification of more potent imipridones, a new class of anti-cancer agents

A. Chi, 2017, Cell cycle.

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

M. Andreeff, W. El-Deiry, T. Batchelor, 2014 .

Prospective, high-throughput molecular profiling of human

P. Wen, K. Ligon, W. Curry, 2012 .

State of the Art Treatment and Surveillance Imaging of Glioblastomas.

Stefan Margiewicz, Rajan Jain, R. Jain, 2017, Seminars in roentgenology.

Management of patients with recurrence of diffuse low grade glioma

D. Brat, J. Olson, T. Ryken, 2015, Journal of Neuro-Oncology.

'Real world' use of a highly reliable imaging sign: 'T2-FLAIR mismatch' for identification of IDH mutant astrocytomas.

Sohil H. Patel, M. Castillo, D. Cahill, 2020, Neuro-oncology.

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

T. Mikkelsen, M. Ahluwalia, M. Rosenfeld, 2018, Clinical Cancer Research.

There is an exception to every rule—T2-FLAIR mismatch sign in gliomas

Sohil H. Patel, R. Jain, M. Snuderl, 2019, Neuroradiology.

Polysomy is associated with poor outcome in 1p19q co-deleted oligodendroglial tumors.

K. Aldape, A. Iafrate, M. Rosenblum, 2019, Neuro-oncology.

Multimodal therapy of an intramedullary cervical primitive neuroectodermal tumor in an adult.

B. Nahed, B. Walcott, A. Chi, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas

T. Mikkelsen, M. Rosenfeld, J. Supko, 2015, Journal of Neuro-Oncology.

Prevalence and pattern of gluteus medius and minimus tendon pathology and muscle atrophy in older individuals using MRI

A. Chi, D. Deely, A. Zoga, 2015, Skeletal Radiology.

EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2

P. Wen, H. Wakimoto, D. Cahill, 2017 .

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

B. Rosen, Jayashree Kalpathy-Cramer, P. Wen, 2017, Journal of Neuro-Oncology.

Pluripotent Chromatin State

Bradley E. Bernstein, B. Bernstein, A. Chi, 2009, Science.

Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.

M. Mehta, F. Lieberman, P. Wen, 2019, Journal of Clinical Oncology.

Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma.

P. Wen, R. Jain, A. Sorensen, 2012 .

In Reply

A. Fathi, A. Chi, 2016, The oncologist.

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI

B. Rosen, Jayashree Kalpathy-Cramer, R. Jain, 2018, Scientific Reports.

The Two Phosphofructokinase Gene Products of Entamoeba histolytica*

R. G. Kemp, Z. Deng, A. Chi, 2001, The Journal of Biological Chemistry.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

B. Rosen, A. Iafrate, P. Wen, 2018, Nature Communications.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Bruce R. Rosen, Ovidiu C. Andronesi, Morteza Esmaeili, 2017, npj Precision Oncology.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy

Maristela L Onozato, A. Iafrate, H. Wakimoto, 2019, Scientific Reports.

Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.

Susan M. Chang, M. Prados, M. Gilbert, 2014 .

RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)

P. Wen, M. Campone, A. Boran, 2018, Neuro-Oncology.

Impact of histopathological transformation and overall survival in patients with progressive anaplastic glioma

Allen L. Ho, D. Louis, D. Cahill, 2016, Journal of Clinical Neuroscience.

Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.

Susan M. Chang, J. Carpten, M. Prados, 2016 .

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.

D. Kondziolka, R. Jain, M. Snuderl, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.